Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Department of Paediatrics, Hong Kong Children's Hospital, Hong Kong SAR, China.
Clin Infect Dis. 2022 Sep 10;75(4):673-681. doi: 10.1093/cid/ciab989.
Age-specific incidence of acute myocarditis/pericarditis in adolescents following Comirnaty vaccination in Asia is lacking. This study aimed to study the clinical characteristics and incidence of acute myocarditis/pericarditis among Hong Kong adolescents following Comirnaty vaccination.
This is a population cohort study in Hong Kong that monitored adverse events following immunization through a pharmacovigilance system for coronavirus disease 2019 (COVID-19) vaccines. All adolescents aged between 12 and 17 years following Comirnaty vaccination were monitored under the COVID-19 vaccine adverse event response and evaluation program. The clinical characteristics and overall incidence of acute myocarditis/pericarditis in adolescents following Comirnaty vaccination were analyzed.
Between 14 June 2021 and 4 September 2021, 33 Chinese adolescents who developed acute myocarditis/pericarditis following Comirnaty vaccination were identified. In total, 29 (87.88%) were male and 4 (12.12%) were female, with a median age of 15.25 years. And 27 (81.82%) and 6 (18.18%) cases developed acute myocarditis/pericarditis after receiving the second and first dose, respectively. All cases are mild and required only conservative management. The overall incidence of acute myocarditis/pericarditis was 18.52 (95% confidence interval [CI], 11.67-29.01) per 100 000 persons vaccinated. The incidence after the first and second doses were 3.37 (95% CI, 1.12-9.51) and 21.22 (95% CI, 13.78-32.28 per 100 000 persons vaccinated, respectively. Among male adolescents, the incidence after the first and second doses were 5.57 (95% CI, 2.38-12.53) and 37.32 (95% CI, 26.98-51.25) per 100 000 persons vaccinated.
There is a significant increase in the risk of acute myocarditis/pericarditis following Comirnaty vaccination among Chinese male adolescents, especially after the second dose.
在亚洲，科兴疫苗接种后青少年急性心肌炎/心包炎的年龄特异性发病率尚不清楚。本研究旨在研究科兴疫苗接种后香港青少年急性心肌炎/心包炎的临床特征和发病率。
这是一项在香港进行的人群队列研究，通过 2019 年冠状病毒病（COVID-19）疫苗的药物警戒系统监测疫苗接种后的不良事件。所有接种科兴疫苗的 12 至 17 岁青少年均在 COVID-19 疫苗不良事件反应和评估计划下进行监测。分析了科兴疫苗接种后青少年急性心肌炎/心包炎的临床特征和总体发病率。
2021 年 6 月 14 日至 2021 年 9 月 4 日，发现 33 例科兴疫苗接种后发生急性心肌炎/心包炎的中国青少年。共有 29 例（87.88%）为男性，4 例（12.12%）为女性，中位年龄为 15.25 岁。第 2 剂和第 1 剂分别有 27 例（81.82%）和 6 例（18.18%）发生急性心肌炎/心包炎。所有病例均为轻症，仅需保守治疗。急性心肌炎/心包炎的总发病率为 18.52（95%置信区间[CI]，11.67-29.01）/10 万人。第 1 剂和第 2 剂的发病率分别为 3.37（95%CI，1.12-9.51）和 21.22（95%CI，13.78-32.28）/10 万人。在男性青少年中，第 1 剂和第 2 剂的发病率分别为 5.57（95%CI，2.38-12.53）和 37.32（95%CI，26.98-51.25）/10 万人。
科兴疫苗接种后，中国男性青少年急性心肌炎/心包炎的风险显著增加，尤其是在接种第 2 剂后。
